Hepatocellular Carcinoma: Screening, Diagnosis, and Management
Natcher Conference Center, NIH
Bethesda, MD
April 1-3, 2004
Summary
Aims of the meeting: To assess the current status of hepatocellular carcinoma (HCC) in the United States, focusing on its prevalence and incidence, methods for screening, means of diagnosis and staging, and management, including the use of liver transplantation. The meeting will be jointly sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Cancer Institute (NCI), the National Institute of Bioengineering, Imaging and Biotechnology (NIBIB), and the Department of Veterans Affairs (VA). The focus of the meeting will be to achieve agreement and develop recommendations based on current trends in the incidence of HCC, its epidemiology, high-risk groups, adequacy and effectiveness of screening in high risk populations, means of early diagnosis, and optimal approaches to management and treatment including surgery, chemoembolization, radiofrequency ablation, and cadaveric and living donor liver transplantation. Another important aim of the meeting is to delineate the specific needs for future basic and clinical research on HCC. A summary of the meeting and its conclusions and recommendations will be submitted for publication. The speakers will be asked to give unbiased and scholarly overviews of the issues to support evidence-based recommendations.
Sponsored by:
National Institute of Diabetes and Digestive and Kidney Diseases
National Cancer Institute
National Institute of Biomedical Imaging and Bioengineering
Department of Veteran AffairsFogarty International Center
Page last updated: November 25, 2008
